$XLRN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ACCELERON PHARMA INC. Get notifications about new insider transactions in ACCELERON PHARMA INC for free.
Page: < prev 1 ... 2 3 4 5 6 7 8 9 10 ... 11 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 30.00 | 5,500 | 165,000 | 22,701 | 28.2 K to 22.7 K (-19.50 %) |
| Jul 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 28,201 | 22.7 K to 28.2 K (+24.23 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 2,000 | 7,760 | 53,751 | |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 55,751 | |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 30.39 | 95 | 2,887 | 35,000 | 35.1 K to 35 K (-0.27 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.68 | 1,905 | 56,540 | 35,095 | 37 K to 35.1 K (-5.15 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 2,000 | 7,760 | 37,000 | 35 K to 37 K (+5.71 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 30.27 | 377 | 11,412 | 35,000 | 35.4 K to 35 K (-1.07 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 29.65 | 4,623 | 137,072 | 35,377 | 40 K to 35.4 K (-11.56 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 40,000 | 35 K to 40 K (+14.29 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 5.08 | 3,367 | 17,104 | 259,133 | |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 3.88 | 15,633 | 60,656 | 27,867 | |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 30.25 | 1,400 | 42,350 | 17,584 | 19 K to 17.6 K (-7.37 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 29.66 | 17,600 | 522,016 | 18,984 | 36.6 K to 19 K (-48.11 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 5.08 | 3,367 | 17,104 | 36,584 | 33.2 K to 36.6 K (+10.14 %) |
| Jul 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 3.88 | 15,633 | 60,656 | 33,217 | 17.6 K to 33.2 K (+88.90 %) |
| Jun 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 1,600 | 8,128 | 22,296 | |
| Jun 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 8,000 | |
| Jun 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 31.07 | 400 | 12,428 | 12,700 | 13.1 K to 12.7 K (-3.05 %) |
| Jun 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 31.57 | 1,000 | 31,570 | 13,100 | 14.1 K to 13.1 K (-7.09 %) |
| Jun 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 31.57 | 5,600 | 176,792 | 32,004 | 37.6 K to 32 K (-14.89 %) |
| Jun 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 1,600 | 8,128 | 37,604 | 36 K to 37.6 K (+4.44 %) |
| Jun 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 36,004 | 32 K to 36 K (+12.50 %) |
| Jun 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 3.88 | 7,701 | 29,880 | 28,539 | |
| Jun 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 3.88 | 7,701 | 29,880 | 22,701 | 15 K to 22.7 K (+51.34 %) |
| Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 9,961 | |
| Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 31.13 | 5,500 | 171,215 | 15,000 | 20.5 K to 15 K (-26.83 %) |
| Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 20,500 | 15 K to 20.5 K (+36.67 %) |
| Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 3.88 | 2,000 | 7,760 | 24,500 | |
| Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 31.11 | 2,000 | 62,220 | 57,656 | 59.7 K to 57.7 K (-3.35 %) |
| Jun 16 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 3.88 | 2,000 | 7,760 | 59,656 | 57.7 K to 59.7 K (+3.47 %) |
| Jun 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 60,751 | |
| Jun 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 35,000 | 30 K to 35 K (+16.67 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 1,500 | 5,820 | 65,751 | |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 67,251 | |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.96 | 200 | 6,592 | 30,000 | 30.2 K to 30 K (-0.66 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.37 | 1,300 | 42,081 | 30,200 | 31.5 K to 30.2 K (-4.13 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 1,500 | 5,820 | 31,500 | 30 K to 31.5 K (+5.00 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.97 | 100 | 3,297 | 30,000 | 30.1 K to 30 K (-0.33 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.49 | 4,900 | 159,201 | 30,100 | 35 K to 30.1 K (-14.00 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 35,000 | 30 K to 35 K (+16.67 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 3.88 | 19,000 | 73,720 | 43,500 | |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.94 | 600 | 19,764 | 17,584 | 18.2 K to 17.6 K (-3.30 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.50 | 18,400 | 598,000 | 18,184 | 36.6 K to 18.2 K (-50.30 %) |
| Jun 09 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 3.88 | 19,000 | 73,720 | 36,584 | 17.6 K to 36.6 K (+108.05 %) |
| May 26 2015 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | J | 0.00 | 5,079 | 0 | 1,705,412 | 1.7 M to 1.7 M (-0.30 %) |
| May 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 1,600 | 8,128 | 23,896 | |
| May 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 12,000 | |
| May 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.20 | 1,400 | 45,080 | 14,100 | 15.5 K to 14.1 K (-9.03 %) |
| May 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 32.41 | 5,600 | 181,496 | 32,004 | 37.6 K to 32 K (-14.89 %) |
| May 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 1,600 | 8,128 | 37,604 | 36 K to 37.6 K (+4.44 %) |
| May 19 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 36,004 | 32 K to 36 K (+12.50 %) |
| May 18 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 3.88 | 2,000 | 7,760 | 26,500 | |
| May 18 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 31.59 | 1,285 | 40,593 | 57,656 | 58.9 K to 57.7 K (-2.18 %) |
| May 18 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 31.32 | 715 | 22,394 | 58,941 | 59.7 K to 58.9 K (-1.20 %) |
| May 18 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 3.88 | 2,000 | 7,760 | 59,656 | 57.7 K to 59.7 K (+3.47 %) |
| May 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 15,461 | |
| May 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 31.81 | 3,900 | 124,059 | 15,000 | 18.9 K to 15 K (-20.63 %) |
| May 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 31.06 | 1,600 | 49,696 | 18,900 | 20.5 K to 18.9 K (-7.80 %) |
| May 18 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 20,500 | 15 K to 20.5 K (+36.67 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | MCGUIRE TERRANCE | Director | Sell | J | 0.00 | 503,991 | 0 | 2,117,747 | 2.6 M to 2.1 M (-19.22 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 72,251 | |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 6,500 | 25,220 | 77,251 | |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 30,000 | 25 K to 30 K (+20.00 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.78 | 1,500 | 47,670 | 25,000 | 26.5 K to 25 K (-5.66 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 32.40 | 100 | 3,240 | 26,500 | 26.6 K to 26.5 K (-0.38 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 31.79 | 4,900 | 155,771 | 26,600 | 31.5 K to 26.6 K (-15.56 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 6,500 | 25,220 | 31,500 | 25 K to 31.5 K (+26.00 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 1.80 | 5,000 | 9,000 | 95,000 | |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 3.88 | 20,000 | 77,600 | 62,500 | |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 1.80 | 5,000 | 9,000 | 17,584 | 12.6 K to 17.6 K (+39.73 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 32.34 | 900 | 29,106 | 12,584 | 13.5 K to 12.6 K (-6.67 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 31.77 | 19,100 | 606,807 | 13,484 | 32.6 K to 13.5 K (-58.62 %) |
| May 13 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 3.88 | 20,000 | 77,600 | 32,584 | 12.6 K to 32.6 K (+158.93 %) |
| May 11 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 28,500 | |
| May 11 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 3.88 | 5,000 | 19,400 | 57,656 | 52.7 K to 57.7 K (+9.50 %) |
| Apr 30 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 1.80 | 5,000 | 9,000 | 2,300 | |
| Apr 30 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Buy | M | 1.80 | 5,000 | 9,000 | 38,200 | 33.2 K to 38.2 K (+15.06 %) |
| Apr 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 16,000 | |
| Apr 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 33.50 | 1,000 | 33,500 | 15,500 | 16.5 K to 15.5 K (-6.06 %) |
| Apr 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 33.53 | 4,000 | 134,120 | 32,004 | 36 K to 32 K (-11.11 %) |
| Apr 21 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 36,004 | 32 K to 36 K (+12.50 %) |
| Apr 17 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 3.88 | 12,000 | 46,560 | 23,500 | |
| Apr 17 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 3.88 | 12,000 | 46,560 | 32,004 | 20 K to 32 K (+59.99 %) |
| Apr 17 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Option Exercise | M | 3.88 | 2,000 | 7,760 | 33,500 | |
| Apr 17 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Sell | S | 33.58 | 2,000 | 67,160 | 52,656 | 54.7 K to 52.7 K (-3.66 %) |
| Apr 17 2015 | XLRN | ACCELERON PHARMA I ... | Ertel Steven D | EVP & Chief Operati ... | Buy | M | 3.88 | 2,000 | 7,760 | 54,656 | 52.7 K to 54.7 K (+3.80 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 83,751 | |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 2,000 | 7,760 | 88,751 | |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 35.50 | 500 | 17,750 | 25,000 | 25.5 K to 25 K (-1.96 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 34.80 | 4,500 | 156,600 | 25,500 | 30 K to 25.5 K (-15.00 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 30,000 | 25 K to 30 K (+20.00 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 35.52 | 250 | 8,880 | 25,000 | 25.3 K to 25 K (-0.99 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 34.82 | 1,750 | 60,935 | 25,250 | 27 K to 25.3 K (-6.48 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 2,000 | 7,760 | 27,000 | 25 K to 27 K (+8.00 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Option Exercise | M | 3.88 | 5,000 | 19,400 | 82,500 | |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 35.45 | 500 | 17,725 | 12,584 | 13.1 K to 12.6 K (-3.82 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 34.80 | 4,500 | 156,600 | 13,084 | 17.6 K to 13.1 K (-25.59 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Buy | M | 3.88 | 5,000 | 19,400 | 17,584 | 12.6 K to 17.6 K (+39.73 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 35.39 | 2,100 | 74,319 | 12,584 | 14.7 K to 12.6 K (-14.30 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 34.75 | 7,900 | 274,525 | 14,684 | 22.6 K to 14.7 K (-34.98 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 35.43 | 500 | 17,715 | 22,584 | 23.1 K to 22.6 K (-2.17 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 34.80 | 4,500 | 156,600 | 23,084 | 27.6 K to 23.1 K (-16.31 %) |
| Apr 08 2015 | XLRN | ACCELERON PHARMA I ... | Nader Francois | Director | Option Exercise | A | 34.14 | 10,000 | 341,400 | 10,000 | |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 5.08 | 800 | 4,064 | 25,496 | |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Option Exercise | M | 0.48 | 4,000 | 1,920 | 20,000 | |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.21 | 200 | 8,242 | 16,500 | 16.7 K to 16.5 K (-1.20 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.60 | 100 | 4,160 | 16,700 | 16.8 K to 16.7 K (-0.60 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.13 | 900 | 37,017 | 16,800 | 17.7 K to 16.8 K (-5.08 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.21 | 800 | 32,968 | 20,004 | 20.8 K to 20 K (-3.85 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 5.08 | 800 | 4,064 | 20,804 | 20 K to 20.8 K (+4.00 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.63 | 721 | 30,015 | 20,004 | 20.7 K to 20 K (-3.48 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Sell | S | 41.07 | 3,279 | 134,669 | 20,725 | 24 K to 20.7 K (-13.66 %) |
| Mar 20 2015 | XLRN | ACCELERON PHARMA I ... | Sherman Matthew L | EVP & Chief Medical ... | Buy | M | 0.48 | 4,000 | 1,920 | 24,004 | 20 K to 24 K (+20.00 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 4,039 | 23,749 | 20,961 | |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 1,461 | 8,591 | 0 | |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.08 | 4,000 | 20,320 | 0 | |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.20 | 220 | 9,064 | 15,000 | 15.2 K to 15 K (-1.45 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.67 | 5,280 | 214,738 | 15,220 | 20.5 K to 15.2 K (-25.76 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 4,039 | 23,749 | 20,500 | 16.5 K to 20.5 K (+24.54 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 1,461 | 8,591 | 16,461 | 15 K to 16.5 K (+9.74 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.05 | 800 | 33,640 | 15,000 | 15.8 K to 15 K (-5.06 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.28 | 3,200 | 132,096 | 15,800 | 19 K to 15.8 K (-16.84 %) |
| Mar 17 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.08 | 4,000 | 20,320 | 19,000 | 15 K to 19 K (+26.67 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 1,500 | 5,820 | 90,751 | |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | M | 3.88 | 5,000 | 19,400 | 92,251 | |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.94 | 200 | 8,188 | 25,000 | 25.2 K to 25 K (-0.79 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.14 | 1,300 | 52,182 | 25,200 | 26.5 K to 25.2 K (-4.91 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 1,500 | 5,820 | 26,500 | 25 K to 26.5 K (+6.00 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.93 | 619 | 25,336 | 25,000 | 25.6 K to 25 K (-2.42 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Sell | S | 40.16 | 4,381 | 175,941 | 25,619 | 30 K to 25.6 K (-14.60 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Buy | M | 3.88 | 5,000 | 19,400 | 30,000 | 25 K to 30 K (+20.00 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 40.93 | 2,501 | 102,366 | 27,584 | 30.1 K to 27.6 K (-8.31 %) |
| Mar 10 2015 | XLRN | ACCELERON PHARMA I ... | Knopf John L | CEO and President | Sell | S | 40.15 | 17,499 | 702,585 | 30,085 | 47.6 K to 30.1 K (-36.77 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.88 | 5,500 | 32,340 | 1,461 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 5.08 | 2,000 | 10,160 | 4,000 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Option Exercise | M | 1.80 | 2,000 | 3,600 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.06 | 101 | 4,248 | 15,000 | 15.1 K to 15 K (-0.67 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.77 | 1,066 | 44,527 | 15,101 | 16.2 K to 15.1 K (-6.59 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.34 | 4,333 | 174,793 | 16,167 | 20.5 K to 16.2 K (-21.14 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.88 | 5,500 | 32,340 | 20,500 | 15 K to 20.5 K (+36.67 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 42.07 | 1 | 42 | 15,000 | 15 K to 15 K (-0.01 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 41.50 | 1,300 | 53,950 | 15,001 | 16.3 K to 15 K (-7.97 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Sell | S | 40.65 | 2,699 | 109,714 | 16,301 | 19 K to 16.3 K (-14.21 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 5.08 | 2,000 | 10,160 | 19,000 | 17 K to 19 K (+11.76 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Quisel John D | SVP Gen. Counsel & ... | Buy | M | 1.80 | 2,000 | 3,600 | 17,000 | 15 K to 17 K (+13.33 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 3,500 | 20,580 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Option Exercise | M | 5.88 | 500 | 2,940 | 0 | |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 42.04 | 100 | 4,204 | 33,200 | 33.3 K to 33.2 K (-0.30 %) |
| Mar 06 2015 | XLRN | ACCELERON PHARMA I ... | Kumar Ravindra | VP & Chief Scientif ... | Sell | S | 41.09 | 366 | 15,039 | 33,300 | 33.7 K to 33.3 K (-1.09 %) |